Cytosorbents

$2.03 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Cytosorbents

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.

Stock Analysis

last close $2.1
1-mo return 2.9%
3-mo return 6.6%
avg daily vol. 92.75T
52-week high 9.8
52-week low 1.69
market cap. $92M
forward pe -
annual div. -
roe -44.3%
ltg forecast -
dividend yield -
annual rev. $41M
inst own. 46.4%
baraka

Subscribe now for daily local and international financial news

Subscribe